Role of dendritic cells in the induction of lymphocyte tolerance
Author
dc.contributor.author
Osorio, Fabiola
Author
dc.contributor.author
Fuentes, Camila
Author
dc.contributor.author
López, Mercedes N.
Author
dc.contributor.author
Salazar Onfray, Flavio
Author
dc.contributor.author
González, Fermín E.
Admission date
dc.date.accessioned
2016-01-12T01:45:12Z
Available date
dc.date.available
2016-01-12T01:45:12Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Front. Immunol. 6:535, 2015
en_US
Identifier
dc.identifier.other
DOI: 10.3389/fimmu.2015.00535
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/136366
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
The ability of dendritic cells (DCs) to trigger tolerance or immunity is dictated by the context in which an antigen is encountered. A large body of evidence indicates that antigen presentation by steady-state DCs induces peripheral tolerance through mechanisms such as the secretion of soluble factors, the clonal deletion of autoreactive T cells, and feedback control of regulatory T cells. Moreover, recent understandings on the function of DC lineages and the advent of murine models of DC depletion have highlighted the contribution of DCs to lymphocyte tolerance. Importantly, these findings are now being applied to human research in the contexts of autoimmune diseases, allergies, and transplant rejection. Indeed, DC-based immunotherapy research has made important progress in the area of human health, particularly in regards to cancer. A better understanding of several DC-related aspects including the features of DC lineages, milieu composition, specific expression of surface molecules, the control of signaling responses, and the identification of competent stimuli able to trigger and sustain a tolerogenic outcome will contribute to the success of DC-based immunotherapy in the area of lymphocyte tolerance. This review will discuss the latest advances in the biology of DC subtypes related to the induction of regulatory T cells, in addition to presenting current ex vivo protocols for tolerogenic DC production. Particular attention will be given to the molecules and signals relevant for achieving an adequate tolerogenic response for the treatment of human pathologies.
en_US
Patrocinador
dc.description.sponsorship
FONDECYT 11130607 FEG
1130320 FS
1130324 ML
National Commission of Scientific and Technological Research (CONICYT)
PAI 82130031 FO